ODG by MCG has adopted updates to its ODG Drug Formulary, which includes U.S. Food and Drug Administration (FDA) approved drugs listed by generic and/or brand names that are commonly prescribed for workplace injuries. All the updates are effective June 26, 2026.
Several states have adopted the ODG formulary for use in their workers’ compensation systems. Examples include Indiana, Montana, and Texas, among several others. These states, to varying degrees, require some type of prior authorization for medications listed as “N” status on the ODG formulary and in some cases for medications not listed on the ODG formulary.
MyMatrixx by Evernorth will make the following changes to our formularies in accordance with the ODG updates and deadline.
If you have questions on these changes and how they will impact your program, please contact your MyMatrixx account team.
New Entries to Appendix A ODG Formulary
| Medication | Use | ODG Status |
|---|---|---|
| Journavx® (suzetrigine) | Non-opioid analgesic for acute pain | N drug |
| Airsupra® (albuterol/budesonide metered dose inhaler) | Asthma treatment | N drug |
| Combivent Respimat® (albuterol/ipratropium soft mist inhaler) | Asthma treatment | N drug |
| Pulmicort Flexhaler® (budesonide dry powder inhaler) | Asthma treatment | N drug |
| Please note: Generically available nebulizer solutions for albuterol/ipratropium and budesonide will remain Y drugs. | ||
About ODG
ODG by MCG offers highly configurable, industry-specific medical treatment and return-to-work solutions, which are used for managing workers’ compensation, disability, and auto liability claim outcomes with evidence-based, data-driven decision support.
MyMatrixx Actions
MyMatrixx maintains ODG-based formularies and will update them in accordance with the above changes. For any changes, please reach out to your MyMatrixx account team.